Tracks nemolizumab use in adolescents and adults with atopic dermatitis
Observes how nemolizumab works for moderate-to-severe atopic dermatitis in routine care.
Plain-language title generated from the registry record
Registry title: Real-world Experience Using Nemolizumab in the Treatment of Moderate-to-Severe Atopic Dermatitis in Adolescents & Adults
Key facts
- Where
- Birmingham, Bridgend, Epsom, Harrogate, Harrow, Kings Lynn, Kingston upon Thames, Kirkcaldy, Leeds, Liverpool, London, Manchester, Metropolitan Borough of Wirral, Redhill, Sandbach, Sheffield, Southampton, Swansea, Watford, Wolverhampton, and York, United KingdomSee the 24 sites
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for teenagers and adults with moderate-to-severe atopic dermatitis who are starting treatment with nemolizumab (Nemluvio®), as decided by their doctor.
- Age
- 12 years and older
- Sex
- All sexes can join.
- Disease stage
- Moderate-to-severe atopic dermatitis (AD).
- Earlier treatment
- Must not have received nemolizumab before. Must not have taken a drug in clinical development or under investigation in the 3 months before the start.
Main reasons for not taking part
- Has a contraindication to nemolizumab (Nemluvio®) under the local package label
- Took a drug under clinical development or investigation within 3 months before baseline
- Received nemolizumab before
- Cannot understand the consent form or complete the study questionnaires
Read by machine on 9 November 2026.
Where in United Kingdom
- BirminghamBirmingham, United KingdomTaking people
- BridgendBridgend, United KingdomTaking people
- EpsomEpsom, United KingdomTaking people
- HarrogateHarrogate, United KingdomTaking people
- HarrowHarrow, United KingdomTaking people
- Kings LynnKings Lynn, United KingdomTaking people
- Kingston upon ThamesKingston upon Thames, United KingdomTaking people
- KirkcaldyKirkcaldy, United KingdomNot yet recruiting
- LeedsLeeds, United KingdomTaking people
- LiverpoolLiverpool, United KingdomTaking people
- LondonLondon, United KingdomTaking people
- LondonLondon, United KingdomTaking people
- LondonLondon, United KingdomTaking people
- LondonLondon, United KingdomTaking people
- ManchesterManchester, United KingdomTaking people
- Metropolitan Borough of WirralMetropolitan Borough of Wirral, United KingdomTaking people
- RedhillRedhill, United KingdomTaking people
- SandbachSandbach, United KingdomTaking people
- SheffieldSheffield, United KingdomTaking people
- SouthamptonSouthampton, United KingdomTaking people
- SwanseaSwansea, United KingdomTaking people
- WatfordWatford, United KingdomTaking people
- WolverhamptonWolverhampton, United KingdomTaking people
- YorkYork, United KingdomTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Galderma R&D
- Trial code
- NCT06988605
- Record updated
- 13 March 2026
- Original description
The main aim of the study is to assess real-world effectiveness of nemolizumab in Atopic Dermatitis (AD) as measured by physician assessment and patient reported outcome (PRO) in clinical practice at Month 6.Read full original descriptionShow less
Real-world Experience Using Nemolizumab in the Treatment of Moderate-to-Severe Atopic Dermatitis in Adolescents & Adults
The main aim of the study is to assess real-world effectiveness of nemolizumab in Atopic Dermatitis (AD) as measured by physician assessment and patient reported outcome (PRO) in clinical practice at Month 6.
Inclusion: Participants who, according to the treating physician's decision and in line with the local package label, start treatment with nemolizumab (Nemluvio®); Adolescent and adult participants aged >=12 years with moderate-to-severe AD; Participants who signed the written informed consent form (ICF) or had it signed by their legal representative.
Exclusion: Participants who received treatment with a drug under clinical development/investigation within 3 months prior to baseline; Participants who received nemolizumab previously; Have contraindication(s) for the use of nemolizumab (Nemluvio®) according to the local package label; Participants who are mentally, physically, or linguistically unable to understand the content of the ICF and/or to complete the study questionnaires.